Abstract
Although immune checkpoint inhibitors (ICIs) have significantly changed the treatment algorithm of patients with advanced non-small cell lung cancer (aNSCLC), the discovery of clinically useful biomarkers remain a challenging issue. Recently, a new score, Patras Immunotherapy Score (PIOS), has been proposed by our group focusing on the results of aNSCLC patients treated with nivolumab or pembrolizumab. The aim of the current study was to investigate the prognostic and predictive value of PIOS in aNSCLC patients treated with combination of immunotherapy with chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
